Phase II trials on latest compound from Addrenex will begin later this year.

Sciele Pharma and Addrenex Pharmaceuticals inked an agreement related to the latter’s hypertension treatment with potential in other indications. ADX415 is a centrally acting alpha adrenergic receptor agonist, specific to Alpha-2 receptors.

Sciele gains the worldwide marketing rights and will pay product development costs, regulatory milestones, and royalties. Sciele and Addrenex expect to begin the Phase II studies in the second half.

This is the firms’ second collaboration; a year ago Sciele licensed CloniBID from Addrenex for the treatment of hypertension. An NDA for CloniBID, a 12-hour, sustained-release formulation of clonidine hydrochloride, was accepted by the FDA in April.

Previous articleElixir Signs License Agreement with Boston University for Use of SIRT1 Modulators
Next articleCase Western, Copernicus Therapeutics, and Polygenix Are Recipients of $3.9M from the Ohio Department of Development